目的 探討茜芷膠囊聯(lián)合米非司酮治療人流術(shù)后持續(xù)陰道出血的臨床療效。方法 選取深圳市龍華新區(qū)人民醫(yī)院2013年3月—2016年3月收治的人流術(shù)后持續(xù)陰道流血患者161例，隨機(jī)分成對照組（80例）和治療組（81例）。對照組患者在常規(guī)治療基礎(chǔ)上口服米非司酮片，12.5 mg/次，1次/d。治療組在對照組的基礎(chǔ)上口服茜芷膠囊，5粒/次，3次/d。兩組患者均連續(xù)治療1周。比較治療后兩組患者臨床療效、宮腔內(nèi)殘留物、術(shù)后出血時(shí)間、術(shù)后陰道出血量、月經(jīng)復(fù)潮時(shí)間以及不良反應(yīng)發(fā)生率。結(jié)果 治療后，對照組和治療組的總有效率分別為81.25%、97.53%，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P < 0.05）。治療后，治療組患者宮腔無殘留物例數(shù)顯著高于對照組患者，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P < 0.05）。治療后，治療組患者術(shù)后陰道出血時(shí)間和術(shù)后陰道出血量分別顯著低于對照組患者，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P < 0.05）。治療后，對照組的不良反應(yīng)發(fā)生率為22.50%，顯著高于治療組的7.41%，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P < 0.05）。結(jié)論 茜芷膠囊聯(lián)合米非司酮治療人流術(shù)后陰道出血不論是在臨床療效方面還是在不良反應(yīng)發(fā)生率方面均要優(yōu)于米非司酮單獨(dú)治療，具有一定的臨床推廣應(yīng)用價(jià)值。

Objective To explore the clinical curative effect of Qianzhi Capsules combined with mifepristone in treatment of continuous vaginal hemorrhage after artificial abortion. Methods Patients (161 cases) with continuous vaginal hemorrhage after artificial abortion in People's Hospital of Longhua in Shenzhen from March 2013 to March 2016 were divided into control (80 cases) and treatment (81 cases) groups. Patients in the control group were po administered with Mifepristone Tablets, 12.5 mg/time, once daily. Patients in the treatment group were po administered with Qianzhi Capsules on the basis of the control group, 5 grains/time, three times daily. Patients in two groups were treated for one week. After treatment, the clinical efficacy, intrauterine residue, postoperative bleeding time, postoperative vaginal bleeding volume, menstruation recovery time, and adverse reactions in two groups after treatment were analyzed and compared. Results After treatment, the clinical efficacies in the control and treatment groups were 81.25% and 97.53% respectively, and there was difference between two groups (P < 0.05). After treatment, patients without intrauterine residue in the treatment group were significantly more than those in the control group, with significant difference between two groups (P < 0.05). After treatment, the postoperative bleeding time and postoperative vaginal bleeding volume in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P < 0.05). After treatment, the adverse reactions rate in the control group was 22.50%, which was significantly higher than 7.41% in the treatment group, with significant difference between two groups (P < 0.05). Conclusion Qianzhi Capsules combined with mifepristone is better than mifepristone alone in aspects of clinical efficacy and adverse reactions rate in treatment of continuous vaginal hemorrhage, which has a certain clinical application value.